Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

25.83 -0.46 (-1.76%)

Streaming Delayed Price Updated: 11:21 AM EDT, Jul 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗

July 20, 2026

Beam Therapeutics' growing pipeline could reward patient investors.

Via The Motley Fool

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗

July 08, 2026

This new technology could one day significantly expand the market for gene-editing biotechs.

Via The Motley Fool

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗

May 25, 2026

Are there significant gains ahead for one (or both) of these innovative biotechs?

Via The Motley Fool

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗

January 12, 2026

Via Stocktwits

Is Beam Therapeutics Gaining or Losing Market Support? ↗

September 22, 2025

Via Benzinga

What Does the Market Think About Beam Therapeutics? ↗

August 25, 2025

Via Benzinga

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances ↗

May 20, 2026

Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics...

Via MarketBeat

Topics Intellectual Property

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

Via The Motley Fool

3 Biotech Stocks That Could Benefit from the Patent Cliff ↗

April 27, 2026

Via MarketBeat

Topics Intellectual Property

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. ↗

April 11, 2026

This precision genetic medicine developer reported a notable insider sale as it advances therapies for rare and serious diseases.

Via The Motley Fool

Topics Regulatory Compliance

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...

Via MarketMinute

Topics Intellectual Property Lawsuit

What's Going On With Beam Therapeutics Stock? ↗

February 24, 2026

Beam Therapeutics (NASDAQ: BEAM) shares are rising Tuesday after the company reported quarterly results.

Via Benzinga

Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 ↗

February 01, 2026

Beam Therapeutics specializes in gene-editing medicines, and recently, the company's Senior Vice President edited out thousands of shares from her portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗

January 29, 2026

Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

Top stock movements in today's session. ↗

January 12, 2026

Via Chartmill

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Beam Therapeutics (BEAM) Earnings Transcript ↗

November 27, 2025

Beam Therapeutics (BEAM) Earnings Transcript

Via The Motley Fool

Topics Death

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam...

Via Benzinga

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Topics Artificial Intelligence

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts

October 09, 2025

New York, NY – October 9, 2025 – In a significant move set to ripple through the biotech sector, Jefferies has initiated coverage of Beam Therapeutics (NASDAQ: BEAM) with a coveted "Buy" rating. This...

Via MarketMinute

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves ↗

October 08, 2025

Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analysts also support Beam Therapeutics (BEAM) and Shopify (SHOP).

Via Benzinga

Topics Artificial Intelligence

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for...

Via MarketMinute

Topics Artificial Intelligence Climate Change Economy

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease ↗

August 15, 2025

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Via Benzinga

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential ↗

June 28, 2025

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies ↗

June 27, 2025

Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Via Investor's Business Daily

Topics Government

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.